Clinical Analysis of 13 Cases of Burkitt Lymphoma and Burkitt-like Lymphoma
10.3969/j.issn.1000-8179.2010.01.002
- VernacularTitle:13例伯基特和伯基特样淋巴瘤的临床特点分析
- Author:
Ningjing LIN
;
Wen ZHENG
;
Yuntao ZHANG
;
Xiaopei WANG
;
Yuqin SONG
;
Yan XIE
;
Meifeng TU
;
Lingyan PING
;
Jun ZHU
- Publication Type:Journal Article
- Keywords:
Burrkitt lymphoma;
Burkitt-like lymphoma;
Clinical charactedstics;
Chemotherapy;
Combination
- From:
Chinese Journal of Clinical Oncology
2010;37(1):5-8
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To summarize the clinical characteristics of Burkitt lymphoma(BL)and Burkitt-like lymphoma(BLL)and the effect of treatment on 13 cases,and to explore the treatment-related complications and optimal treatment.Methods:Clinical data of 13 BL and BLL patients treated between August 1996 and October 2008 in our hospital were retrospectively analyzed.All of these patients received chemotherapy as the first-line treatment.The efficacy and adverse reactions were evaluated.Results:Of the 13 patients,there were 12 males and 1 female,with a median age of 15 years(ranging from 11 to 62).There were 3 stage Ⅰ cases,2 stage Ⅱ cases,2 stage Ⅲ cases,and 6 stage Ⅳ cases.The advanced stage(stage Ⅲ and Ⅳ)patients accounted for 61.5%(8 cases).CNS was involved in 4 cases and bone marrow was involved in 2 cases at diagnosis.The commonly involved sites included superficial lymph nodes(61.5%),abdominal organs(53.8%),and celiac and retro-pentoneal lymph nodes(38.5%).B symptoms were observed in 7 patients(53.8%).Serum lactate dehydrogenase level was elevated in 8 of 10 cases,while serum udc acid level was elevated in 1 of 10 cases.Eleven patients were diagnosed as BL and 2 patients were diagnosed as BLL.Of the 13 patients,11(84.6%) achieved complete remission(CR)or CR/unconfirmed(CRu),and 1 patient(7.7%) got partial remission(PR).Dudng the follow-up of 8 months(ranging from 5 to 35),6 patients were still alive.The 1-year overall survival,progression-free survival and disease-free survival were 56.98%,32.31% and 39.77%,respectively.Nine patients(69.2%)developed grade Ⅲ or Ⅳ myelosuppression.Conclusion:Intensive short-course chemotherapy is the optimal first-line treatment for BL and BLL.
